Structural, molecular, and cellular biology of PKD2 allosteric modulators as novel therapeutics for cancer KU Leuven
Recently, we applied computer aided drug design to develop
allosteric, isoenzyme specific inhibitors of Protein Kinase D2 (PKD2).
We have now validated our compounds as truly PKD2 isoenzyme
specific, with promising properties against pancreatic cancer,
glioblastoma and multiple myeloma (cancers of high unmet medical
need). While we have designed the compounds to bind a specific
location in PKD2, the crystal ...